NCT03301454 2026-03-18
E-DIS2
Centre Oscar Lambret
Phase 2 Terminated
Clinical Trials
469 trialsNCT03652298 2026-03-13
NeuroPrevPTSD
Centre Oscar Lambret
Phase 2 Terminated
NCT04166383 2026-03-10
VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT04327700 2026-03-05
Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib
Wake Forest University Health Sciences
Phase 2 Terminated
NCT04975516 2026-03-03
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Terminated
NCT03785210 2026-02-23
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05567835 2026-02-23
TOGAR
Baylor College of Medicine
Phase 2 Terminated
NCT03165721 2026-02-18
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT06851104 2026-02-18
A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence
Guangxi Medical University
Phase 2 Terminated
NCT02738606 2026-02-17
Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05442749 2026-02-17
PARPi-PANC
Centre Leon Berard
Phase 2 Terminated
NCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT05733611 2026-02-02
RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC
Replimune Inc.
Phase 2 Terminated
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT06739252 2026-01-28
Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA
Peking University
Phase 2 Terminated
NCT06006923 2026-01-20
Regorafenib in Combination With Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer
University of Pittsburgh
Phase 2 Terminated
NCT05987176 2026-01-14
NELMAS
Imperial College London
Phase 2 Terminated
NCT06332079 2026-01-05
HAITI
Gruppo Oncologico del Nord-Ovest
Phase 2 Terminated
NCT03844750 2025-12-31
Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases
University of California, San Francisco
Phase 2 Terminated
NCT05998447 2025-12-16
GEN-001 Plus Pembrolizumab for Patients With Advanced Refractory Biliary Tract Cancer
Genome & Company
Phase 2 Terminated
NCT05114213 2025-12-05
MASPAC
Ludwig-Maximilians - University of Munich
Phase 2 Terminated
NCT04779151 2025-12-01
NIRADO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT04844970 2025-11-17
Anamorelin Study for Advanced Pancreatic Cancer
Lahey Clinic
Phase 2 Terminated
NCT05256381 2025-11-17
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Sotio Biotech Inc.
Phase 2 Terminated
NCT04504916 2025-11-10
MK-2140-002
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT00422877 2025-10-16
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
American Regent, Inc.
Phase 2 Terminated
NCT04050462 2025-10-16
Nivolumab Combined With BMS-986253 in HCC Patients
NYU Langone Health
Phase 2 Terminated
NCT04363801 2025-10-09
DisTinGuish
Leap Therapeutics, Inc.
Phase 2 Terminated
NCT04189445 2025-10-08
Futibatinib in Patients With Specific FGFR Aberrations
Taiho Oncology, Inc.
Phase 2 Terminated
NCT05199285 2025-10-03
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab
Academic and Community Cancer Research United
Phase 2 Terminated
NCT04985604 2025-10-02
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Day One Biopharmaceuticals, Inc.
Phase 2 Terminated
NCT02982694 2025-10-01
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Vall d'Hebron Institute of Oncology
Phase 2 Terminated
NCT04659603 2025-10-01
CARMEN-BT01
Sanofi
Phase 2 Terminated
NCT05350501 2025-09-29
CLAUDE
Enterome
Phase 2 Terminated
NCT05221320 2025-09-25
Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies
BioMed Valley Discoveries, Inc
Phase 2 Terminated
NCT05537402 2025-09-24
LOST-B
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT05678257 2025-09-12
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
Phase 2 Terminated
NCT00766142 2025-08-29
COCHISE
Institut Bergonié
Phase 2 Terminated
NCT05009979 2025-08-28
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05071053 2025-08-22
CARMEN-GC01
Sanofi
Phase 2 Terminated
NCT04057365 2025-08-13
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
Massachusetts General Hospital
Phase 2 Terminated
NCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT03320629 2025-08-06
A Study of Apatinib Plus Radiotherapy and S-1 for Treatment of Refractory or Metastatic Esophageal Squamous Cell Carcinoma
Hebei Medical University Fourth Hospital
Phase 2 Terminated
NCT05619172 2025-07-24
A Study of Nanrilkefusp Alfa (SOT101) in Combination With Cetuximab to Evaluate the Efficacy and Safety in Patients With Colorectal Cancer
Sotio Biotech Inc.
Phase 2 Terminated
NCT04992507 2025-07-10
Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT04786600 2025-07-01
A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial
University of Florida
Phase 2 Terminated
NCT05330429 2025-07-01
ELEVATE CRC
Gilead Sciences
Phase 2 Terminated
NCT06370663 2025-06-25
First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC
Shandong Cancer Hospital and Institute
Phase 2 Terminated